WallStreetZenWallStreetZen

NASDAQ: VERV
Verve Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VERV past revenue growth

How has VERV's revenue growth performed historically?
Company
505.77%
Industry
145.63%
Market
17.92%
VERV's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VERV's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VERV's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VERV earnings and revenue history

Current Revenue
$11.8M
Current Earnings
-$200.1M
Current Profit Margin
-1,701.5%

VERV Return on Equity

Current Company
-39.3%
Current Industry
-63.5%
Current Market
188%
VERV's Return on Equity (-39.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VERV announces earnings.

VERV Return on Assets

Current Company
-30.9%
Current Industry
2.9%
VERV is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VERV Return on Capital Employed

Current Company
-27.92%
Current Industry
19.5%
VERV has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VERV vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VERV$11.76M-$187.55M-$200.07M+505.77%N/A
AVBP$0.00-$69.33M-$69.33MN/AN/A
KALV$0.00-$107.49M-$108.30M-100.00%N/A
ATXS$0.00-$72.89M-$72.89MN/AN/A
VALN$167.08M-$81.85M-$110.25M+4.76%N/A
View Top Biotech Stocks

VERV earnings dates

Next earnings date
May 7, 2024

Verve Therapeutics Earnings & Revenue FAQ

What were VERV's earnings last quarter?

On Invalid Date, Verve Therapeutics (NASDAQ: VERV) reported Q4 2023 earnings per share (EPS) of -$0.69, up 6.15% year over year. Total Verve Therapeutics earnings for the quarter were -$48.35 million. In the same quarter last year, Verve Therapeutics's earnings per share (EPS) was -$0.65.

If you're new to stock investing, here's how to buy Verve Therapeutics stock.

What was VERV's earnings growth in the past year?

As of Q2 2024, Verve Therapeutics's earnings has grown year over year. Verve Therapeutics's earnings in the past year totalled -$200.07 million.

What is VERV's earnings date?

Verve Therapeutics's earnings date is Invalid Date. Add VERV to your watchlist to be reminded of VERV's next earnings announcement.

What was VERV's revenue last quarter?

On Invalid Date, Verve Therapeutics (NASDAQ: VERV) reported Q4 2023 revenue of $5.14 million up 408.3% year over year. In the same quarter last year, Verve Therapeutics's revenue was $1.01 million.

What was VERV's revenue growth in the past year?

As of Q2 2024, Verve Therapeutics's revenue has grown 505.77% year over year. This is 360.14 percentage points higher than the US Biotechnology industry revenue growth rate of 145.63%. Verve Therapeutics's revenue in the past year totalled $11.76 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.